openPR Logo
Press release

Global Pompe Disease Industry Growth and Analysis 2016 – 2024

07-21-2017 06:01 PM CET | Health & Medicine

Press release from: Transparency Market Research

Global Pompe Disease Industry Growth and Analysis 2016 – 2024

Pompe disease is a rare, progressive, autosomal recessively inherited metabolic disorder, and is often a fatal muscular disease that affects one of the lysosomal enzymes. Pompe disease can also be called as a glycogen storage disease or acid alpha-glycosidase deficiency or GAA deficiency. It mainly occurs due to accumulation of glycogen in some tissues and organs, particularly muscles, leading to abnormal functioning. The inability of breaking the lysosomal glycogen lies in the mutation of a gene responsible for production of the enzyme acid alpha-glycosidase. This enzyme breaks glycogen into simpler form i.e. glucose but a mutation in the GAA gene prevents this activity. The stoppage of glycogen breakdown causes massive cellular dysfunction, with the marked involvement of the cardiac, smooth, and skeletal muscle. 

View Report @ http://www.transparencymarketresearch.com/pompe-disease-market.html

Pompes disease is categorized on the basis of disease severity, disease progression and age, such as infantile-onset, non-classic infantile-onset and late onset. Within few months of birth, the infantile onset of Pompes disease starts showing its symptoms such as enlarged liver(hepatomegaly),muscle weakness(myopathy), heart defect, and poor muscle tone (hypotony).The infants affected with this disease face challenges of weight gain as well as hampered growth and breathing problems. The affected infant may have large protruding tongue. If untreated, the infant may die of heart failure in the first year of life itself. Non-Classic infantile-onset is usually seen at the age of 1 year. The disease symptoms include poor motor skills and a delayed muscle progress .They may show signs of hearing impairment and abnormally large heart. The muscle weakness may seriously lead to breathing problems. The Late-onset marks its symptoms by later stages of childhood, adolescent age or in adulthood. This form of late onset is a bit milder than the previous ones and doesn’t involve heart. The muscle weakness is generally observed in the legs, trunk and breathing muscles. The progress of the disorder in the muscles controlling breathing will ultimately lead to the respiratory failure.

Get accurate market forecast and analysis on the Pompe Disease Market. Request a sample to stay abreast on the key trends impacting this market.

http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=14102

Pompes disease can occur in various age groups and population across the world. The occurrence of the disease is 1 in 40,000 births in the U.S. In many cases, the people suffering from Pompes Disease in late onset of the disease remain undiagnosed. The symptoms of Pompes Disease are observed due to the complete or partial deficiency of the GAA enzyme. Diagnosis of Pompe disease can be performed by GAA activity assay. Following are the tests for the detection of Pompe disease:

Sequencing of the GAA gene
GAA activity assay in blood, cultured amniocytes, chorionic villi and cultured skin fibroblasts.
The marker, urinary hexose tetrasaccharide can be used to keep a track of patients suffering from Pompe disease
Cross Reactive Immunological Material (CRIM) analysis
Pompe disease can be treated by symptomatic, supportive and disease-specific ways. As the disease involves impairment of cardiac, respiratory and muscular systems, the treatment necessitates requirement of specialists with expertise in all these disorders. Cardiologists, dieticians, pediatricians, orthopedists may need to co-ordinate and design a well collaborated treatment plan for the patient. The US Food and Drug Administration has approved an enzyme replacement therapy- Myozyme® for the infantile onset of Pompe disease suffering patients of less than 8 years old. Whereas Lumizyme® is used for patients older than 8 years of age. The genetically engineered human GAA enzyme is administered intravenously every two weeks.

Increasing developments in the gene therapy and enzyme replacement therapies are driving factors for the growth of Pompe disease market. However, affordability of the expensive therapy treatments may pose a potential threat to these markets in developing markets. Major market players in the field of Pompe Disease therapeutics are Genzyme, BioMarin Pharmaceutical, and Amicus Therapeutics.There are some key vendors like Audentes Therapeutics, EpiVax, Oxyrane, Sangamo BioSciences, and Valerion Therapeutics.

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Each TMR syndicated research report covers a different sector – such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.

US Office Contact

90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: www.transparencymarketresearch.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Global Pompe Disease Industry Growth and Analysis 2016 – 2024 here

News-ID: 636838 • Views: 252

More Releases from Transparency Market Research

Water Purifier Market - Competitive Dynamics, Trends, Forecast 2027
Transparency Market Research delivers key insights on the global water purifier market. In terms of revenue, the global water purifier market is estimated to expand at a CAGR of ~ 9% during the forecast period, owing to numerous factors, regarding which, TMR offers thorough insights and forecasts in the water purifier market report. Browse Report Details: https://www.transparencymarketresearch.com/water-purifier-market-2017-2025.html Water purifiers help in removing bacterial contaminants and viruses from water and make it safe
Sheet Face Masks Market Leading Vendors: Sephora Inc. Boss Biological Technique …
The Sheet face masks market promises robust growth during 2018-2026, thanks to rising demand for sheet face mask products. Growing demand for personal hygiene products, and beautification products are expected to drive significant growth. The rising demand for natural ingredients in sheet face masks products is expected to emerge as the largest trend in the market. Browse Report Details: https://www.transparencymarketresearch.com/sheet-face-masks-market.html Sheet face masks are often associated with a certain prestige and rejuvenating
Global Nail Care Market to Reach US$ 20,940.2 Mn by 2027
According to a new research report published by Transparency Market Research titled ‘Nail Care Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019–2027,’ the global nail care market is expected to reach a value of US$ 20,940.2 Mn by 2027, expanding at a CAGR of 8.4% from 2019 to 2027. In terms of volume, the market is expected to reach 1,494.2 Mn units by 2027, expanding at
Industrial Dispensing System and Equipment Market to Reach ~ US$ 16.7 Bn by 2027
Transparency Market Research delivers key insights on the global industrial dispensing system and equipment market. In terms of revenue, the global industrial dispensing system and equipment market is estimated to expand at a CAGR of ~ 6% during the forecast period, owing to numerous factors, regarding which, TMR offers thorough insights and forecasts in the industrial dispensing system and equipment market report. Browse Report Details: https://www.transparencymarketresearch.com/industrial-dispensing-system-equipment-market.html Industrial dispensing systems and equipment are

All 5 Releases


More Releases for Pompe

Pompe Disease Therapeutic Market - Attractive Growth Opportunities 2017 - 2025
Manufacturers are focusing on finding new solutions by expanding their pipeline to cater the demand for pompe disease therapeutics market. For instance, in September, 2017, Avrobio Inc. expanded their products pipeline with gene therapy to treat pompe disease by utilizing a proprietary lysosomal targeting sequence to deliver high levels of enzyme to lysosomes. Furthermore, in October 2017, Amicus Therapeutics received orphan drug designation to ATB200/AT2221 from the U.S. FDA for
Pompe Disease Market Growth Analysis up to 2024
Pompe disease is a rare, progressive, autosomal recessively inherited metabolic disorder, and is often a fatal muscular disease that affects one of the lysosomal enzymes. Pompe disease can also be called as a glycogen storage disease or acid alpha-glycosidase deficiency or GAA deficiency. It mainly occurs due to accumulation of glycogen in some tissues and organs, particularly muscles, leading to abnormal functioning. The inability of breaking the lysosomal glycogen lies
Pompe Disease Market Intelligence with Competitive Landscape 2024
Pompe disease is a rare, progressive, autosomal recessively inherited metabolic disorder, and is often a fatal muscular disease that affects one of the lysosomal enzymes. Pompe disease can also be called as a glycogen storage disease or acid alpha-glycosidase deficiency or GAA deficiency. It mainly occurs due to accumulation of glycogen in some tissues and organs, particularly muscles, leading to abnormal functioning. The inability of breaking the lysosomal glycogen lies
Pompe Disease Market Size – Industry Share Report 2024
Pompe disease is a rare, progressive, autosomal recessively inherited metabolic disorder, and is often a fatal muscular disease that affects one of the lysosomal enzymes. Pompe disease can also be called as a glycogen storage disease or acid alpha-glycosidase deficiency or GAA deficiency. It mainly occurs due to accumulation of glycogen in some tissues and organs, particularly muscles, leading to abnormal functioning. The inability of breaking the lysosomal glycogen lies
Pompe Disease Market : Size, Status and Forecast 2016 - 2024
Pompe disease is a rare, progressive, autosomal recessively inherited metabolic disorder, and is often a fatal muscular disease that affects one of the lysosomal enzymes. Pompe disease can also be called as a glycogen storage disease or acid alpha-glycosidase deficiency or GAA deficiency. It mainly occurs due to accumulation of glycogen in some tissues and organs, particularly muscles, leading to abnormal functioning. The inability of breaking the lysosomal glycogen lies
Pompe Disease Market to Reflect Impressive Growth Rate by 2024
Pompe disease is a rare, progressive, autosomal recessively inherited metabolic disorder, and is often a fatal muscular disease that affects one of the lysosomal enzymes. Pompe disease can also be called as a glycogen storage disease or acid alpha-glycosidase deficiency or GAA deficiency. It mainly occurs due to accumulation of glycogen in some tissues and organs, particularly muscles, leading to abnormal functioning. The inability of breaking the lysosomal glycogen lies